FDA — authorised 24 July 2019
- Application: NDA210134
- Marketing authorisation holder: AMPHASTAR PHARMS INC
- Local brand name: BAQSIMI
- Indication: POWDER — NASAL
- Status: approved
🇺🇸 Intranasal glugagon in United States
FDA authorised Intranasal glugagon on 24 July 2019
Marketing authorisations
FDA
- Status: approved
Intranasal glugagon in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Intranasal glugagon approved in United States?
Yes. FDA authorised it on 24 July 2019; FDA has authorised it.
Who is the marketing authorisation holder for Intranasal glugagon in United States?
AMPHASTAR PHARMS INC holds the US marketing authorisation.